EP1030679A4 - Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase - Google Patents

Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Info

Publication number
EP1030679A4
EP1030679A4 EP98957325A EP98957325A EP1030679A4 EP 1030679 A4 EP1030679 A4 EP 1030679A4 EP 98957325 A EP98957325 A EP 98957325A EP 98957325 A EP98957325 A EP 98957325A EP 1030679 A4 EP1030679 A4 EP 1030679A4
Authority
EP
European Patent Office
Prior art keywords
urokinase
degradation
compositions
methods
plasminogen activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98957325A
Other languages
German (de)
English (en)
Other versions
EP1030679A1 (fr
Inventor
Douglas Cines
Abd Al-Roof Higazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP1030679A1 publication Critical patent/EP1030679A1/fr
Publication of EP1030679A4 publication Critical patent/EP1030679A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
EP98957325A 1997-10-17 1998-10-15 Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase Withdrawn EP1030679A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6227497P 1997-10-17 1997-10-17
US62274P 1997-10-17
PCT/US1998/021800 WO1999020295A1 (fr) 1997-10-17 1998-10-15 Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Publications (2)

Publication Number Publication Date
EP1030679A1 EP1030679A1 (fr) 2000-08-30
EP1030679A4 true EP1030679A4 (fr) 2003-03-05

Family

ID=22041403

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98957325A Withdrawn EP1030679A4 (fr) 1997-10-17 1998-10-15 Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase

Country Status (5)

Country Link
EP (1) EP1030679A4 (fr)
JP (1) JP2001520200A (fr)
AU (1) AU739373B2 (fr)
CA (1) CA2306953A1 (fr)
WO (1) WO1999020295A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034776A2 (fr) * 2000-10-26 2002-05-02 K.U.Leuven Research And Development Epitopes de pai-1
US7271143B1 (en) * 2001-07-10 2007-09-18 Thrombotech Ltd. Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
US20030211095A1 (en) * 2002-05-08 2003-11-13 Abd. Al-Roof Higazi Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy
CA2694214A1 (fr) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides issus de l'inhibiteur 1 de l'activateur du plasminogene et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320840A2 (fr) * 1987-12-18 1989-06-21 BEHRINGWERKE Aktiengesellschaft Peptides, leur procédé de préparation, anticorps contre ceux-ci, et utilisation de ces anticorps pour bloquer l'activité PAI-1 du sang humain
WO1994028145A2 (fr) * 1993-06-01 1994-12-08 Chiron Corporation Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene
WO1995002413A1 (fr) * 1993-07-16 1995-01-26 Cancerforskningsfondet Af 1989 Suppression d'inhibiteurs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
ZA928954B (en) * 1991-12-24 1993-05-19 Akzo Nv Peptides immunochemically reactive with antibodies directed against hepatitis non-A, non-B virus.
US5674078A (en) * 1996-01-23 1997-10-07 The Whitaker Corporation Multi-directional interface header assembly

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320840A2 (fr) * 1987-12-18 1989-06-21 BEHRINGWERKE Aktiengesellschaft Peptides, leur procédé de préparation, anticorps contre ceux-ci, et utilisation de ces anticorps pour bloquer l'activité PAI-1 du sang humain
WO1994028145A2 (fr) * 1993-06-01 1994-12-08 Chiron Corporation Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene
WO1995002413A1 (fr) * 1993-07-16 1995-01-26 Cancerforskningsfondet Af 1989 Suppression d'inhibiteurs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AL-ROOF HIGAZI A ET AL: "SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR BOUND TO ITS RECEPTOR IS RELATIVELY RESISTANT TO PLASMINOGEN ACTIVATOR INHIBITORTYPE 1", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 87, no. 9, 1 May 1996 (1996-05-01), pages 3545 - 3549, XP001037493, ISSN: 0006-4971 *
See also references of WO9920295A1 *

Also Published As

Publication number Publication date
EP1030679A1 (fr) 2000-08-30
WO1999020295A1 (fr) 1999-04-29
AU1360999A (en) 1999-05-10
AU739373B2 (en) 2001-10-11
CA2306953A1 (fr) 1999-04-29
JP2001520200A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
PL333505A1 (en) Benzamido-aldehydes and their application as inhibitors of cysteinic proteases
EP1023017A4 (fr) Colle de fibrine sans fibrinogene et compositions bioscellantes et procedes
PL327658A1 (en) Disinfecting compositions and methods of disinfecting surfaces
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
PL333434A1 (en) Aminoguanidines and alkoxyguanidines as inhibitors of proteases
EP1018987A4 (fr) Neocartilage et ses methodes d'utilisation
AU9312898A (en) Foaming urethane composition and methods of using such compositions
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
PL335168A1 (en) Compositions for and methods of reducing intracocular hypertension
HUP9701018A3 (en) Xantine derivatives having (omega-amino)-hydroxyalkynyl side-chain and pharmaceutical compositions containing them
ZA988017B (en) Parp inhibitors pharmaceutical compositions comprising same and methods of using same
ZA985028B (en) Method of treating liver tumours and pharmaceutical compositions for use therein
AU4243397A (en) Methods for in vivo reduction of iron levels and compositions useful therefor
IL120311A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
IL120310A0 (en) Serine protease inhibitors and pharmaceutical compositions containing them
PL332137A1 (en) Injectable preparations of avermerctins and milbemycins
PL327945A1 (en) Disinfecting compositions and methods of disinfecting surfaces
LT99141A (en) Pharmaceutical compositions of tizoxanide and nitazoxanide
ZA976791B (en) Composition comprising mupirocin and chlohexidine
AU7431796A (en) Brain-associated inhibitor of tissue-type plasminogen activator
EP0857174A4 (fr) Fragments d'activateurs de type urokinase du plasminogene
EP1030679A4 (fr) Compositions et procedes permettant de favoriser l'internalisation et la degradation de l'activateur du plasminogene de type urokinase
IL132516A (en) Pharmaceutical compositions of tizoxanide and nitazoxanide
IL111501A0 (en) Pharmaceutical compositions comprising lys-plasminogen and tissue plasminogen activator (t-PA) for the treatment of coronary thrombosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/08 A, 7A 61K 38/10 B, 7A 61K 38/16 B, 7A 61P 35/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20041022